Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumi-NHL: AZD4512 alone or with other anticancer agents in relapsed/refractory B-cell non-Hodgkin lymphoma
2025-522371-29-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label trial of AZD4512 in mature B-cell lymphoma and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by AstraZeneca. Primary endpoints: Dose-limiting toxicities, Adverse events and 2 more. Planned start Nov 2025; status: authorised.
02
Drugs
AZD4512
03
Conditions
mature B-cell lymphomanon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2025-522371-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522371-29-00.